Looking to mine more gold from its respiratory drug franchise, Astrazeneca plc offered up full data from the pivotal phase III trials of benralizumab at the European Respiratory Society (ERS) meeting in London, seeking to position the company's first biologic respiratory medicine as a key differentiator in the space.